The era of targeted therapy for hyperlipidemia
Despite a variety of lipid-lowering drugs, mostly pelleted, aimed at reducing low-density lipoprotein cholesterol and triglycerides, only a small number of patients achieve their target levels. The reasons are insufficient adherence to treatment, rare use of combined lipid-lowering therapy regimens...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2024-10-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/6038 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849340882757615616 |
|---|---|
| author | U. V. Chubykina A. V. Tyurina M. V. Ezhov |
| author_facet | U. V. Chubykina A. V. Tyurina M. V. Ezhov |
| author_sort | U. V. Chubykina |
| collection | DOAJ |
| description | Despite a variety of lipid-lowering drugs, mostly pelleted, aimed at reducing low-density lipoprotein cholesterol and triglycerides, only a small number of patients achieve their target levels. The reasons are insufficient adherence to treatment, rare use of combined lipid-lowering therapy regimens by attending physicians, low availability and high cost of injected lipid-lowering agents. With the advent of technologies for targeted therapy for hyperlipidemia, a new era in cardiology opens. These innovations will lead to higher goal achievement rates through a personalized and precision approach to hyperlipidemia treatment. Novel lipid-lowering drugs are directed at the molecular targets of hypercholesterolemia, hyperlipoproteinemia(a) and hypertriglyceridemia. The review purpose is to systematize following information about innovative lipid-lowering drugs: mechanism of action, stage of development, effectiveness and safety. |
| format | Article |
| id | doaj-art-e21b417a94c64b7eafa7fb8bb1d3ccda |
| institution | Kabale University |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2024-10-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-e21b417a94c64b7eafa7fb8bb1d3ccda2025-08-20T03:43:46Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202024-10-0129810.15829/1560-4071-2024-60384173The era of targeted therapy for hyperlipidemiaU. V. Chubykina0A. V. Tyurina1M. V. Ezhov2Chazov National Medical Research Center of CardiologyChazov National Medical Research Center of CardiologyChazov National Medical Research Center of CardiologyDespite a variety of lipid-lowering drugs, mostly pelleted, aimed at reducing low-density lipoprotein cholesterol and triglycerides, only a small number of patients achieve their target levels. The reasons are insufficient adherence to treatment, rare use of combined lipid-lowering therapy regimens by attending physicians, low availability and high cost of injected lipid-lowering agents. With the advent of technologies for targeted therapy for hyperlipidemia, a new era in cardiology opens. These innovations will lead to higher goal achievement rates through a personalized and precision approach to hyperlipidemia treatment. Novel lipid-lowering drugs are directed at the molecular targets of hypercholesterolemia, hyperlipoproteinemia(a) and hypertriglyceridemia. The review purpose is to systematize following information about innovative lipid-lowering drugs: mechanism of action, stage of development, effectiveness and safety.https://russjcardiol.elpub.ru/jour/article/view/6038hypercholesterolemialipoprotein(a)triglyceridesatherosclerosistargeted therapy |
| spellingShingle | U. V. Chubykina A. V. Tyurina M. V. Ezhov The era of targeted therapy for hyperlipidemia Российский кардиологический журнал hypercholesterolemia lipoprotein(a) triglycerides atherosclerosis targeted therapy |
| title | The era of targeted therapy for hyperlipidemia |
| title_full | The era of targeted therapy for hyperlipidemia |
| title_fullStr | The era of targeted therapy for hyperlipidemia |
| title_full_unstemmed | The era of targeted therapy for hyperlipidemia |
| title_short | The era of targeted therapy for hyperlipidemia |
| title_sort | era of targeted therapy for hyperlipidemia |
| topic | hypercholesterolemia lipoprotein(a) triglycerides atherosclerosis targeted therapy |
| url | https://russjcardiol.elpub.ru/jour/article/view/6038 |
| work_keys_str_mv | AT uvchubykina theeraoftargetedtherapyforhyperlipidemia AT avtyurina theeraoftargetedtherapyforhyperlipidemia AT mvezhov theeraoftargetedtherapyforhyperlipidemia AT uvchubykina eraoftargetedtherapyforhyperlipidemia AT avtyurina eraoftargetedtherapyforhyperlipidemia AT mvezhov eraoftargetedtherapyforhyperlipidemia |